Convalescent plasma (CP) from COVID-19 recovered patients contains polyclonal anti-SARS-CoV-2 antibodies, can be collected in large quantities at relatively low costs and was used as a therapeutic strategy in previous viral outbreaks8,9. The gene discussed is CP; the disease is COVID-19.